Living donor liver transplantation in polycystic liver disease.
In the current Model for End-Stage Liver Disease system, patients with polycystic liver disease (PCLD) who have a poor quality of life secondary to their massive hepatomegaly are no longer competitive for a deceased donor liver transplant if their liver function is well preserved. Traditionally, a caval resection has been advocated in these patients because of the difficulty of the hepatectomy with hepatomegaly, which makes living donation impossible. This series looks at 3 patients who underwent a caval sparing hepatectomy and subsequent living donor liver transplantation (LDLT) for PCLD. Graft and patient survival was 100%, and there were few complications in either donors or recipients. LDLT is an ideal option for patients with PCLD and preserved liver function but poor quality of life.
Mekeel
Kristin L
KL
Division of Transplantation, Department of Surgery, Mayo Clinic Arizona, Phoenix, AZ 85054, USA. mekeel.kristin@mayo.edu
Moss
Adyr A
AA
Reddy
Kunam S
KS
Douglas
David D
DD
Vargas
Hugo E
HE
Carey
Elizabeth J
EJ
Byrne
Thomas J
TJ
Harrison
M E
ME
Rakela
Jorge
J
Mulligan
David C
DC
D000328:Adult; D003560:Cysts / Q000150:complications / Q000401:mortality / Q000503:physiopathology / Q000601:surgery*; D005260:Female; D006085:Graft Survival; D006498:Hepatectomy; D006529:Hepatomegaly / Q000209:etiology / Q000601:surgery; D006801:Humans; D008107:Liver Diseases / Q000150:complications / Q000401:mortality / Q000503:physiopathology / Q000601:surgery*; D008111:Liver Function Tests; D016031:Liver Transplantation; D019520:Living Donors; D008875:Middle Aged; D018579:Patient Selection; D011788:Quality of Life; D012189:Retrospective Studies; D016896:Treatment Outcome